Home > News > Industry > Pharma News > Mac-Chem Products Boisar...

Mac-Chem Products Boisar facility Successfully Renews EU GMP Certification

By - Ruchika Sharma
Published On 2024-04-19 12:08 GMT   |   Update On 2024-04-19 12:08 GMT

Mumbai: Mac-Chem Products (India) Pvt. Ltd. (Mac-Chem) announced today the successful renewal of its European Union Goods Manufacturing Practices) (EU-GMP certification for its manufacturing facility in Boisar. The approval marks a significant milestone for Mac-Chem in its journey of global leadership. The audit was conducted in October 2023 by Swissmedic Swiss Agency for Therapeutic...

Login or Register to read the full article
Register Now

Mumbai: Mac-Chem Products (India) Pvt. Ltd. (Mac-Chem) announced today the successful renewal of its European Union Goods Manufacturing Practices) (EU-GMP certification for its manufacturing facility in Boisar. The approval marks a significant milestone for Mac-Chem in its journey of global leadership. The audit was conducted in October 2023 by Swissmedic Swiss Agency for Therapeutic Products. 

Speaking on the development, Mr. Manish Jain, Director at Mac-Chem said, “We are delighted with the successful renewal of our EU-GMP certification. The achievement affirms our commitment to the highest standards of quality and compliance aligning with the European regulations.
The timely approval further reaffirms our commitment for delivering high-quality pharma products that positively impact patient care globally.”
The EU-GMP certification underlines the Boisar facility’s capabilities to ensure consistent and controlled production in accordance with EU quality standards. The facility produces a wide range of APIs, with a special focus on oncology and other niche specialty segments.
Also Read:Glenmark Pharmaceuticals Gets CDSCO Panel Nod to Study Lobeglitazone Sulfate, Glimepiride FDC Table
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Bayer, Evotec ink pact to advance precision cardiology
Janssen to adopt Johnson & Johnson brand in UK
Boehringer Ingelheim gets USFDA nod for high-concentration, citrate-free formulation of Cyltezo to treat multiple chronic inflammatory diseases
Labcorp gets USFDA nod for Companion Diagnostic for use with Pfizer hemophilia B Gene Therapy
Alkem Laboratories Gets CDSCO Panel Nod to Study Amoxicillin,Clavulanate Powder for reconstitution into suspension
Bharat Biotech Chief Dr Krishna M Ella named as new President of Indian Vaccine Manufacturers Association
Pneubevax 14 safe, immunogenic in 6-8 week old infants: Biological E
Sun Pharma served with tax demand of Rs 1.11 crore